Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01, Briefing.com reports. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the previous year, the business posted ($0.80) EPS.

Denali Therapeutics Trading Up 12.2 %

Shares of NASDAQ DNLI traded up $2.05 during midday trading on Wednesday, hitting $18.90. The company's stock had a trading volume of 2,702,102 shares, compared to its average volume of 1,180,243. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.31. The firm has a market cap of $2.69 billion, a P/E ratio of -17.50 and a beta of 1.39. The business's 50 day moving average is $18.80 and its two-hundred day moving average is $18.84.

Analyst Upgrades and Downgrades

DNLI has been the topic of several research reports. Wedbush decreased their price target on shares of Denali Therapeutics from $31.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday. Stifel Nicolaus decreased their target price on shares of Denali Therapeutics from $26.00 to $22.00 and set a "hold" rating on the stock in a research report on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $95.00 price target on shares of Denali Therapeutics in a research report on Wednesday. UBS Group decreased their price objective on Denali Therapeutics from $70.00 to $32.00 and set a "buy" rating on the stock in a research report on Tuesday, April 9th. Finally, The Goldman Sachs Group lowered their price objective on Denali Therapeutics from $73.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, February 29th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $40.22.

Insider Buying and Selling

In other Denali Therapeutics news, insider Carole Ho sold 2,784 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $17.29, for a total value of $48,135.36. Following the sale, the insider now owns 145,010 shares in the company, valued at $2,507,222.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $18.37, for a total transaction of $30,604.42. Following the completion of the sale, the director now owns 121,375 shares of the company's stock, valued at $2,229,658.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Carole Ho sold 2,784 shares of the company's stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $17.29, for a total value of $48,135.36. Following the completion of the sale, the insider now owns 145,010 shares of the company's stock, valued at $2,507,222.90. The disclosure for this sale can be found here. In the last three months, insiders sold 110,955 shares of company stock valued at $2,218,802. Insiders own 7.90% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.